ID   Calu-1 W5S2
AC   CVCL_WS71
SY   W5S2
DR   cancercelllines; CVCL_WS71
DR   Wikidata; Q93442856
RX   Patent=US6004761;
RX   PubMed=2430697;
CC   Population: Caucasian.
CC   Sequence variation: Gene deletion; HGNC; HGNC:11998; TP53; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3493; Lung squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0608 ! Calu-1
SX   Male
AG   47Y
CA   Cancer cell line
DT   Created: 05-07-19; Last updated: 19-12-24; Version: 9
//
RX   Patent=US6004761;
RA   Linsley P.S., Horn D., Brown J.P.;
RT   "Method for detecting cancer using monoclonal antibodies to new mucin
RT   epitopes.";
RL   Patent number US6004761, 21-Dec-1999.
//
RX   PubMed=2430697;
RA   Linsley P.S., Ochs V., Horn D., Ring D.B., Frankel A.E.;
RT   "Heritable variation in expression of multiple tumor associated
RT   epitopes on a high molecular weight mucin-like antigen.";
RL   Cancer Res. 46:6380-6386(1986).
//